Patent estate
NAPO PHARMS INC — Patent Portfolio
1 drug with active patents · 2 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Mytesi (CROFELEMER)
Cliff 2031 · 5yMethod of Use 2
-
US8962680
Vuln 68
2031-10-31
This patent protects methods for treating diarrhea, including HIV-associated diarrhea, by administering an inhibitor of chloride-ion transport, such as crofelemer.
-
US9585868
Vuln 68
2031-10-31
This patent protects methods for treating diarrhea, including HIV-associated diarrhea, by administering an inhibitor of chloride-ion transport, such as crofelemer.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 2 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track NAPO PHARMS INC's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export